BioInvent Initiates Phase 1 Trial with Subcutaneous Formulation of BI-1206

LUND, SE / ACCESSWIRE / December 19, 2022 / BioInvent International (STO:BINV)Starting dose predicted to provide drug exposure at levels already shown to have elicited responsesSubcutaneous formulation is significantly more convenient administration …